Le Lézard3h
Vertex Announces FDA Approval of JOURNAVXtm (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...
Business Wire3h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...
Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
AI-driven virtual CGM data boosts understanding of T1D risks
This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its ...
Opinion
The New Times on MSN4dOpinion
Lifestyle control: The key to managing and preventing diabetes
Someone is considered to be diabetic if the blood glucose/sugar levels are persistently above normal. People with diabetes usually have problems converting food nutrients into energy for their body ...
What Really Works for Nerve Pain
Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...